NF-κB and Its Role in Checkpoint Control.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 May 2020
Historique:
received: 06 05 2020
revised: 25 05 2020
accepted: 28 05 2020
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 2 4 2021
Statut: epublish

Résumé

Nuclear factor-κB (NF-κB) has been described as one of the most important molecules linking inflammation to cancer. More recently, it has become clear that NF-κB is also involved in the regulation of immune checkpoint expression. Therapeutic approaches targeting immune checkpoint molecules, enabling the immune system to initiate immune responses against tumor cells, constitute a key breakthrough in cancer treatment. This review discusses recent evidence for an association of NF-κB and immune checkpoint expression and examines the therapeutic potential of inhibitors targeting either NF-κB directly or molecules involved in NF-κB regulation in combination with immune checkpoint blockade.

Identifiants

pubmed: 32486375
pii: ijms21113949
doi: 10.3390/ijms21113949
pmc: PMC7312739
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
Cyclooxygenase Inhibitors 0
Cytokines 0
Immune Checkpoint Inhibitors 0
NF-kappa B 0
Protein Kinase Inhibitors 0
Toll-Like Receptors 0
Tumor Necrosis Factor-alpha 0
Cyclooxygenase 2 EC 1.14.99.1
ErbB Receptors EC 2.7.10.1
Cyclin-Dependent Kinase 4 EC 2.7.11.22
Pentoxifylline SD6QCT3TSU

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Cell. 2019 Jan 3;73(1):22-35.e6
pubmed: 30527665
Int J Cancer. 2010 Aug 15;127(4):759-67
pubmed: 20518016
Cells. 2016 Mar 29;5(2):
pubmed: 27043634
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
J Clin Invest. 2018 Aug 31;128(9):3926-3940
pubmed: 29952768
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Eur J Immunol. 2002 Aug;32(8):2095-104
pubmed: 12209621
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):330-336
pubmed: 30446226
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Oncoimmunology. 2015 Aug 12;5(2):e1074374
pubmed: 27057439
Oncogene. 2015 Oct 1;34(40):5187-97
pubmed: 25659581
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126
pubmed: 30297397
NPJ Precis Oncol. 2017;1:
pubmed: 28989978
Nature. 2019 May;569(7756):428-432
pubmed: 31043740
Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):213-220
pubmed: 31058656
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Nat Cell Biol. 2007 Dec;9(12):1419-27
pubmed: 18037881
Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
J Dermatol Sci. 2005 Nov;40(2):95-103
pubmed: 16085391
J Surg Res. 2019 Aug;240:115-123
pubmed: 30927618
J Hepatol. 2006 Oct;45(4):520-8
pubmed: 16876901
J Exp Clin Cancer Res. 2018 Oct 12;37(1):248
pubmed: 30314513
Immunol Rev. 2013 Mar;252(1):41-51
pubmed: 23405894
Cancer Res. 2016 Dec 1;76(23):6964-6974
pubmed: 27671674
Int J Oncol. 2018 Oct;53(4):1469-1480
pubmed: 30066852
Oncotarget. 2017 Mar 14;8(11):18021-18030
pubmed: 28152514
Trends Immunol. 2004 Jun;25(6):280-8
pubmed: 15145317
PLoS One. 2013;8(1):e55183
pubmed: 23372833
J Immunol. 2004 Aug 1;173(3):2011-22
pubmed: 15265936
Cancer Invest. 2008 Oct;26(8):816-21
pubmed: 18608206
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Biochem Biophys Res Commun. 2015 Jul 17-24;463(1-2):95-101
pubmed: 25998384
Sci Rep. 2017 Aug 31;7(1):10255
pubmed: 28860576
PLoS One. 2015 Apr 06;10(4):e0123410
pubmed: 25844720
Front Immunol. 2018 Sep 27;9:2129
pubmed: 30356906
J Biol Chem. 2018 Oct 5;293(40):15483-15496
pubmed: 30135206
PLoS One. 2013 Nov 04;8(11):e78070
pubmed: 24223761
Anticancer Res. 2003 Jan-Feb;23(1A):363-98
pubmed: 12680238
Nat Med. 2015 Jun;21(6):560-2
pubmed: 25939061
Sci Rep. 2016 Jan 25;6:19740
pubmed: 26804478
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
Oncogene. 2017 Feb 23;36(8):1069-1079
pubmed: 27524414
Ann Oncol. 2016 Aug;27(8):1492-504
pubmed: 27207108
Oncogene. 2017 Jul 13;36(28):4037-4046
pubmed: 28288138
J Hematol Oncol. 2019 Sep 5;12(1):92
pubmed: 31488176
Immunity. 1997 Feb;6(2):165-74
pubmed: 9047238
J Exp Clin Cancer Res. 2019 Sep 11;38(1):397
pubmed: 31506076
J Exp Med. 2005 Jan 3;201(1):105-15
pubmed: 15630139
J Clin Invest. 2019 May 21;129(8):3347-3360
pubmed: 31112529
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
J Cell Biochem. 2007 Dec 1;102(5):1087-94
pubmed: 17910035
Nucleic Acids Res. 2008 Mar;36(5):1665-80
pubmed: 18263619
Mol Cancer. 2011 Dec 23;10:152
pubmed: 22195643
J Cell Biochem. 2018 Dec;119(12):9997-10004
pubmed: 30145830
Cancer Manag Res. 2018 Oct 26;10:4653-4667
pubmed: 30464589
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Gut. 2016 Jul;65(7):1151-64
pubmed: 26033966
J Clin Oncol. 2011 Dec 20;29(36):4828-36
pubmed: 22042955
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
N Engl J Med. 2018 Mar 22;378(12):1165
pubmed: 29562154
Sci Adv. 2020 Feb 05;6(6):eaay7785
pubmed: 32076650
Immunol Cell Biol. 2012 May;90(5):483-91
pubmed: 22410872
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
Oncology. 2010;78(3-4):181-8
pubmed: 20414006
Curr Cancer Drug Targets. 2018;18(8):737-748
pubmed: 28669345
Blood. 2018 Jan 4;131(1):58-67
pubmed: 29118008
Oncogene. 2006 Oct 30;25(51):6887-99
pubmed: 17072334
Blood. 2008 Apr 1;111(7):3635-43
pubmed: 18223165
J Clin Pathol. 2018 Mar;71(3):189-194
pubmed: 29097600
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
Ann Oncol. 2014 Oct;25(10):1935-40
pubmed: 25009014
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
J Immunol. 1999 Sep 15;163(6):3474-83
pubmed: 10477620
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
Cell Cycle. 2016;15(6):819-26
pubmed: 27029529
Cancer Res. 2003 Dec 1;63(23):8293-301
pubmed: 14678988
EMBO J. 2003 Mar 17;22(6):1302-12
pubmed: 12628923
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Heliyon. 2018 Dec 18;4(12):e01039
pubmed: 30603685
Mol Nutr Food Res. 2015 Nov;59(11):2143-54
pubmed: 26375873
Cancer Res. 2018 Jan 1;78(1):205-215
pubmed: 29263152
Expert Opin Ther Targets. 2010 Jan;14(1):45-55
pubmed: 20001209
Oncoimmunology. 2018 Feb 1;7(5):e1423170
pubmed: 29721376
PLoS One. 2013 Apr 09;8(4):e61602
pubmed: 23585913
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
Am J Cancer Res. 2018 Jul 01;8(7):1307-1316
pubmed: 30094103
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
Front Pharmacol. 2018 Nov 06;9:1255
pubmed: 30459616
Mol Cell. 2019 Jan 3;73(1):1-2
pubmed: 30609388
J Immunol. 2007 May 15;178(10):6634-41
pubmed: 17475895
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
Cell Res. 2019 Oct;29(10):846-861
pubmed: 31481761
Apoptosis. 2009 Apr;14(4):348-63
pubmed: 19212815
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Expert Opin Drug Saf. 2017 Apr;16(4):465-469
pubmed: 28271729
J Thorac Oncol. 2016 Nov;11(11):1879-1890
pubmed: 27346415
Cancer Res. 2013 Jan 15;73(2):745-55
pubmed: 23149915
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Cancer Immunol Immunother. 2018 Feb;67(2):271-283
pubmed: 29090321
Genes (Basel). 2018 Jan 09;9(1):
pubmed: 29315242
Clin Cancer Res. 2015 Sep 1;21(17):3969-76
pubmed: 25944800
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Blood. 2007 Jul 1;110(1):296-304
pubmed: 17363736
Onco Targets Ther. 2016 Oct 26;9:6619-6629
pubmed: 27822067
Oncoimmunology. 2017 Jul 26;6(11):e1356145
pubmed: 29147605
Cancer Res. 2009 Sep 1;69(17):7013-21
pubmed: 19706766
Nat Commun. 2017 Dec 22;8(1):2256
pubmed: 29273790
Nature. 2006 May 25;441(7092):431-6
pubmed: 16724054
J Virol. 2017 Oct 13;91(21):
pubmed: 28835489
Oral Oncol. 2015 Mar;51(3):221-8
pubmed: 25500094
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
Int Immunopharmacol. 2015 Oct;28(2):836-40
pubmed: 25887265
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Oncotarget. 2015 Jun 10;6(16):14209-19
pubmed: 25895031
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
J Biol Chem. 2004 Jan 23;279(4):2559-67
pubmed: 14600152
Cancer Res. 2015 Dec 1;75(23):5034-45
pubmed: 26573793
Cell. 2007 Sep 7;130(5):918-31
pubmed: 17803913
Adv Immunol. 2014;124:95-136
pubmed: 25175774
Pancreatology. 2018 Apr;18(3):328-333
pubmed: 29525378
Oncotarget. 2015 Nov 24;6(37):40247-54
pubmed: 26450901
Oncotarget. 2015 Oct 6;6(30):30251-62
pubmed: 26388611
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22699-22709
pubmed: 31636208
Cell Death Differ. 2020 Jun;27(6):1765-1781
pubmed: 31802034
Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9
pubmed: 20018552
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Science. 2011 Apr 29;332(6029):600-3
pubmed: 21474713
Annu Rev Immunol. 2004;22:531-62
pubmed: 15032588
Cancer Sci. 2019 May;110(5):1665-1675
pubmed: 30844110
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Cancer Discov. 2013 Dec;3(12):1355-63
pubmed: 24078774
Oncogene. 2019 Jun;38(23):4452-4466
pubmed: 30755733
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
Oncotarget. 2015 Nov 24;6(37):40327-36
pubmed: 26515597
Cold Spring Harb Perspect Biol. 2010 May;2(5):a000182
pubmed: 20452952
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Lung Cancer. 2015 Sep;89(3):311-9
pubmed: 26122346
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
J Neuroimmunol. 2004 Oct;155(1-2):172-82
pubmed: 15342209
Curr Med Chem. 2007;14(3):367-76
pubmed: 17305539
BMC Genomics. 2010 Jan 11;11:22
pubmed: 20064247

Auteurs

Annika C Betzler (AC)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Marie-Nicole Theodoraki (MN)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Patrick J Schuler (PJ)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Johannes Döscher (J)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Simon Laban (S)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Thomas K Hoffmann (TK)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Cornelia Brunner (C)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH